Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells

Figure 5 Dynamic changes in the percentage of splenic Tregs after cisplatin (DDP) administration. BALB/c WT mice were injected s.c. with 1 × 10⁶ CT-26 cells 7 d before treatment. The tumor-bearing mice were treated with DDP (2.5 mg/kg, i.p., D0) and the spleen single cell suspensions prepared to analyze the Treg percentage by flow cytometry at the indicated post-treatment time points (A). Typical data from a representative experiment are shown (B). Points: mean Treg cell percentage (n = 3); Bars: SD. All experiments were performed twice with similar results. NS: Normal saline; DDP: Cisplatin.